In survey, PhRMA member companies highlight impact of IPI on R & D

One of the biggest myths regarding the administration ’s proposed International Pricing Index (IPI) Model is that it will have little to no effect on biomedical research and development (R&D). Secretary of Health and Human ServicesAlex Azar has said that the reduction in R&D couldn ’t possibly be more than 1 percent. In contrast, PhRMA estimates that the impact of the model on R&D is much greater with a disproportionately negative effect on innovative medicines, including new medicines that are meeting unmet medical needs for previously untreatable conditions, like some cancers and potential cures for genetic disorders.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Research and Investment Part B Source Type: news